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Abstract
Introduction: Psoriasis is an inflammatory and immunological cutaneous disease. The high
morbidity in patients with psoriasis results from severe clinical manifestations and/or adverse effects
of treatment. The Undersea and Hyperbaric Medical Society and Federal Medicare and Medicaid
Services have approved the use of hyperbaric oxygen (HBO2) for more than 15 indications, including
wound healing, infections and late effects of radiation, which are largely unresponsive to conventional
treatments. Accumulated data show that HBO2 has anti-inflammatory effects and other positive
influences on the immune system, making it a rational treatment in the management of psoriasis
plaques and arthritis.
Case presentation: We present the cases of two patients with long histories of psoriasis vulgarus
who exhibited marked improvement with use of HBO2. The first patient was 40 years old and had
pustular psoriasis and psoriatic arthritis. He was treated with six sessions of HBO2 (at 2.8
atmospheres of pressure for 60 minutes), which successfully controlled his symptoms. At the 18-
month post-treatment follow up, the patient exhibited complete remission of psoriasis and marked
improvement in psoriatic arthritis without medication. The second patient was 55 years old with
extensive psoriatic lesions, and exhibited marked improvement within 15 sessions of HBO2. No
adverse effects of HBO2 were identified.
Conclusions: HBO2 may possess potential therapeutic efficacy in the management of psoriasis. We
outline the pathogenesis of psoriasis and the selective anti-inflammatory and immunosuppressive
effects of HBO2. We hope that this will provide a basis for elucidating the mechanisms of action and
consequently pave the way for further controlled studies.
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Introduction
Psoriasis is a chronic, remitting and relapsing, immune-
mediated inflammatory skin disorder with a strong genetic
predisposition. It is among the most common immune-
mediated diseases in humans, affecting 2.6% of the US
population, and has significant social and economic
impact. Current topical therapies used to manage psoriasis
include steroids, vitamin D derivatives, retinoids, immu-
nosuppressants, anthralin, coal tar ointment, and several
other agents [1-5]. These drugs often have adverse effects
that may be poorly tolerated. Light therapy includes
ultraviolet B phototherapy or psoralen and ultraviolet
A (PUVA) photochemotherapy. However, increased
rates of nonmelanoma skin cancer have been observed
following PUVA therapy [6]. Systemic therapies for
psoriasis include methotrexate, cyclosporine, oral reti-
noids, and biologic therapies. A recent report reviewed the
effectiveness and safety of the biologics alefacept, efalizu-
mab, etanercept, and infliximab [7]. In addition to the
reported adverse effects of the drugs, it was found that up
to 40% of patients did not use their medication as
directed.
Hyperbaric oxygen (HBO2) treatment is defined as
breathing pure (100%) oxygen under conditions of
increased atmospheric pressure. This results in elevated
arterial oxygen tension to 2,000 mmHg or greater, which
provides tissues with abundant oxygen. Possible compli-
cations of HBO2 therapy include barotrauma, oxygen
toxicity (affecting the central nervous system and lungs),
claustrophobia and anxiety, and ocular effects such as
myopia and cataract. HBO2 promotes proliferation of
fibroblasts, epithelial cells, and blood vessels in a wound.
It can increase the killing ability of leukocytes and is lethal
to certain anaerobic bacteria. Furthermore, it inhibits toxin
formation by certain anaerobes, increases the flexibility of
red cells, reduces tissue edema, and conserves intracellular
ATP.
The Undersea and Hyperbaric Medical Society and the
Federal Center for Medicare and Medicaid Services have
approved the use of HBO2 in 14 indications including gas
gangrene, necrotizing soft-tissue infections, diabetic foot
ulcer, compromised grafts and flaps, bone infection,
intracranial abscess, anemia and blood loss, crush injury,
carbon monoxide and cyanide poisoning, radiation
complications, decompression sickness, and gas embo-
lism. HBO2 has potential effects on mediators of
inflammation and the immune response. Our recent
reviews [8,9] support the contention that HBO2 has anti-
inflammatory and immunosuppressive properties. These
properties make this treatment a potentially useful
intervention that should be tested in the management of
psoriasis and psoriatic arthritis.
Case presentation
Case 1
A 40-year-old man with disseminated erythrodermic
psoriasis with pustules presented with arthralgias. He had
a history of psoriasis vulgaris from infancy, diagnosed by
skin biopsy, and had been followed by dermatologists. He
had also had psoriatic arthritis since childhood. Physical
examination revealed erythematous scaly plaques on his
elbows, trunk and umbilical area, perineum and legs
(Figure 1). He had interphalangeal distal joint involvement
and spondylitis. His medical history was uneventful, with
no evidence of underlying systemic disease and he was not
taking any medications at the time of presentation.
He requested a hyperbaric consultation after reading a
newspaper article reporting on the use of HBO2 to treat
psoriasis in a study conducted in Cuba. At the hospital he
was evaluated to determine whether he was a suitable
candidate for HBO2 therapy. After he had given informed
consent, he underwent HBO2 therapy at 2.8 atmospheres for
60 minutes, once a day (5 days per week). The patient
underwent a total of eight sessions, resulting in significant
amelioration of symptoms (Figure 2). The patient did not
receive any topical treatment before or duringHBO2 therapy.
Most of the psoriatic lesions were cleared, with marked
reduction in itching and scaling. No side effect was
reported with the use of HBO2. The patient also reported
less pain in his hands and joints after the eight sessions of
HBO2. Follow up at 18 months revealed that the patient
had only mild skin symptoms with degenerative changes
of the arthritis.
Case 2
A 55-year-old man was referred for HBO2 for management
of chronic bilateral leg ulcers and osteomyelitis. In
addition, he had extensive psoriasis vulgaris (Figure 3).
He had a long history of psoriasis vulgaris, which had been
diagnosed by skin biopsy and followed by a dermatolo-
gist. His current medications at the time of admission to
the hyperbaric department were topical mineral oil,
Eucerin Calming Creme, and diphenhydramine 50 three
times a day. He had erythema, and his skin was scaling and
itching.
He underwent daily HBO2 at 2 atmospheres for 90
minutes, once a day (5 days per week). After six sessions
his erythema, scaling and itching were reduced in severity,
and after 15 sessions he had improved further (Figure 4).
No adverse effect was reported with the use of HBO2.
Discussion
The results presented here demonstrate the effectiveness of
HBO2 in alleviating signs and symptoms of psoriasis in
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two patients. No adverse effects were reported during or
after treatment with HBO2.
Leukocytes, cytokines, and keratinocyte growth or differ-
entiation abnormalities are involved in psoriatic skin
lesions. Psoriasis vulgaris is a T-cell-driven disease, with
type I (interferon-ү-producing) T cells predominating in
skin lesions [10,11]. A lymphocytic infiltrate in psoriasis
plaques consists of a mixture of activated CD4+ and CD8+
T cells; the latter predominate in lesional epidermis and
CD4+ cells in the dermis [12]. The therapeutic benefit of
immunosuppressive drugs supports the view that activated
T cells are pathogenic effectors of psoriasis [10]. Dendritic
cells are found in psoriatic skin lesions, producing
interleukin (IL)-12 and IL-23. Cytokine changes in
psoriatic lesions consist of elevated levels of interferon-ү,
tumor necrosis factor (TNF)-a, numerous interleukins
(such as IL-1, IL-2, IL-6, IL-8, IL-12, IL-17, and IL-19),
and multiple chemokines (MIG/CXCL9, IP-10/CXCL10,
I-TAC/CXCL11, and MIP3a/CCL20) [11]. IL-12 p40
mRNA and expression of interferon-ү, inducible nitric
Figure 2. Patient 1 after treatment with hyperbaric oxygen
(Front View).
Figure 3. Patient 1 before treatment with hyperbaric oxygen
(Back View).
Figure 4. Patient 1 after treatment with hyperbaric oxygen
(Back View).
Figure 1. Patient 1 before treatment with hyperbaric oxygen
(Front View).
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oxide synthase, B7-1, and TNF-a are elevated in psoriatic
tissue [11]. A rheumatoid-like pattern has been identified
as one of the most common types of psoriatic arthritis.
Autoantibodies directed against nuclear antigens, cytoker-
atins, epidermal keratins, and heat shock proteins have
also been reported in psoriatic arthritis.
HBO2 suppresses the proliferation of macrophages and
the formation of foam cells in atherosclerotic lesions [12].
HBO2 also intensifies the suppressive function of T
lymphocytes, normalizes cell-bound immunity, and
decreases the serum concentration in immune complexes
[13]. The immunosuppressive effects of HBO2 include
suppression of autoimmune symptoms, decreased pro-
duction of IL-1 and CD4+ cells, and increased percentage
and absolute number of CD8+ cells [9]. In addition, long-
term HBO2 exposure suppresses development of auto-
immune symptoms such as proteinuria, facial erythema,
Figure 6. Patient 2 after treatment with hyperbaric oxygen
(Side View Torso).
Figure 8. Patient 2 after treatment with hyperbaric oxygen
(Side View Legs).
Figure 5. Patient 2 before treatment with hyperbaric oxygen
(Side View Torso).
Figure 7. Patient 2 before treatment with hyperbaric oxygen
(Side View Legs).
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and lymphadenopathy. HBO2 decreases the CD4:CD8
ratio and proliferation of lymphocytes, and activates
neutrophils to migrate to regions of high oxygen tension
[14]. HBO2 suppresses TNF-a production induced by
lipopolysaccharide, lipid A, and phytohemagglutinin A
[15]. A marked decrease in IL-1 and IL-2 production, and a
significant decrease in prostaglandin E2 production have
been observed.
The positive clinical effects that HBO2 has in the treatment
of chronic inflammation may relate to its effects on
secretion of IL-1, IL-6, and TNF-a. The effects of HBO2 on
prostaglandin, nitric oxide, and cytokines involved in
wound pathophysiology and inflammation in particular
were recently reviewed [8]. That review indicates that
HBO2 has important effects on the biology of cytokines
and other mediators of inflammation. HBO2 causes
downregulation of cytokines and upregulation of growth
factors. It transiently suppresses stimulus-induced proin-
flammatory cytokine production and affects the liberation
of TNF-a and endothelins. Vascular endothelial growth
factor levels are significantly increased with HBO2 therapy,
whereas levels of prostaglandin E2 and cyclo-oxygenase-2
mRNA are markedly reduced. Therefore, the anti-inflam-
matory and immunosuppressive properties of HBO2
might account for its efficacy in the cases presented here.
Conclusions
Our case reports, although suggestive, do not allow one to
conclude that HBO2 treatment is useful in the treatment of
psoriasis, because this condition can improve sponta-
neously. We emphasize that the findings presented here
require confirmation by further controlled studies before a
definitive conclusion may be drawn. We hope that our
findings will also stimulate further investigation of the
therapeutic potential of HBO2 alone or in combination
with other modalities such as phototherapy in psoriasis.
HBO2 therapy may have a place in the management of
psoriasis. Further studies including large numbers of
patients and involving monitoring cytokines and inflam-
matory mediators will help us to explore the effect of
hyperoxygenation on psoriasis and to elucidate its
mechanism of action.
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